+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gynecological Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Gynecological Cancer Drugs Market - Global Forecast 2026-2032- Product Image
New

Gynecological Cancer Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887490
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gynecological cancer drugs market is evolving rapidly as new scientific approaches, industry realignments, and shifting reimbursement frameworks redefine growth opportunities, clinical practice, and commercial strategy. Senior decision-makers must anticipate and navigate these multi-layered changes to sustain market relevance and advance patient care.

Market Snapshot: Gynecological Cancer Drugs Market Growth Trajectory

The gynecological cancer drugs market is projected to expand significantly, growing from USD 11.63 billion in 2025 to USD 13.06 billion in 2026 and on to USD 26.63 billion by 2032, representing a compound annual growth rate (CAGR) of 12.56%. This strong upward trend is fueled by the rapid uptake of precision therapies, dynamic reimbursement processes, and a renewed emphasis on reliable supply chains across all core regions. Increasing attention to clinical differentiation and operational efficiency is shaping competitor moves and partnership strategies.

Scope & Segmentation of the Gynecological Cancer Drugs Market

  • End Users: Clinics, including oncology and outpatient practices, as well as hospitals—both private and public—and specialty centers, each presenting unique operational and patient management considerations.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies, which address diverse logistical challenges and patient access models across market segments.
  • Administration Routes: Intraperitoneal, intravenous (both bolus and infusion), and oral formats in capsule and tablet types, meeting the needs for flexible delivery and patient adherence.
  • Drug Classes: Chemotherapy agents, such as alkylating agents, platinum compounds, and taxanes; hormonal therapies, including anti-estrogens and aromatase inhibitors; immunotherapies, with emphasis on checkpoint inhibitors and vaccines; and targeted therapies encompassing angiogenesis inhibitors, PARP inhibitors, and tyrosine kinase inhibitors.
  • Cancer Types: Cervical, endometrial, ovarian, and vulvar cancers, each with individual clinical, diagnostic, and treatment pathways that shape therapy demand and inform resource allocation.
  • Regional Coverage: Americas; Europe, Middle East & Africa; and Asia-Pacific, regions that exhibit varied regulatory complexities, diagnostic infrastructures, and care delivery mechanisms, all of which impact market penetration and product adoption.

Key Takeaways for Senior Decision-Makers

  • Precision oncology advances and an increased focus on biomarker-driven drug development are reshaping research and clinical priorities, compelling more targeted therapy investments and supportive diagnostic services.
  • Regulatory and payer shifts, including more rigorous requirements for real-world outcomes, prompt earlier data collection strategies and collaborative reimbursement discussions between manufacturers and health systems.
  • Coordinated care pathways and integration of multidisciplinary teams are increasingly central in delivering effective, accessible treatment, especially as outpatient and specialty centers gain prominence within the broader care continuum.
  • Expanding availability of generics and biosimilars exerts downward pricing pressure, leading both established and emerging players to prioritize combination therapy research and technology-enhanced care models to sustain differentiation.
  • Digital tools for remote monitoring and decentralized clinical trials are improving patient engagement and enabling new evidence-generation approaches, especially valuable in regions with diverse healthcare landscapes.
  • Greater market and supply-chain complexity call for robust manufacturing, sourcing, and distribution strategies that can weather policy shifts and economic fluctuations, reducing the risk of interruptions in drug availability.

Tariff Impact: Trade Policy and Supply-Chain Resilience

Recent tariff and trade policy changes have introduced cost volatility, challenging manufacturers to rethink supplier selection and inventory strategies. Hospitals are emphasizing long-term contracting and contingency plans, especially for therapies requiring specialized handling. Distribution partners must manage cost variability while expanding collaboration with contract manufacturers and regional production hubs to enhance continuous supply and maintain agility amid regulatory shifts.

Methodology & Data Sources

The research combines primary insights from oncology clinicians, pharmacists, distributors, and industry executives with secondary analysis of authoritative literature, regulatory documents, clinical trial datasets, and real-world evidence. Analytical rigor is maintained through scenario planning, outlier validation, and expert review to ensure actionable, reproducible results.

Why This Report Matters for Your Strategic Planning

  • Provides practical frameworks for aligning product portfolios and commercial models with scientific and regulatory shifts in the gynecological cancer drugs market.
  • Supports organizational agility by equipping teams to build resilient supply chains and anticipate operational adjustments following policy or tariff changes.
  • Enables evidence-based decisions on payer engagement and market entry, optimizing go-to-market strategies for each unique treatment segment and region.

Conclusion: Outlook for Innovation and Market Leadership

Organizations that embrace technological and regulatory shifts while maintaining a focus on supply resilience and patient-centric evidence will be best positioned to drive sustained market performance and improve patient access.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gynecological Cancer Drugs Market, by Administration Route
8.1. Intraperitoneal
8.2. Intravenous
8.2.1. Bolus
8.2.2. Infusion
8.3. Oral
8.3.1. Capsule
8.3.2. Tablet
9. Gynecological Cancer Drugs Market, by Drug Class
9.1. Chemotherapy Agents
9.1.1. Alkylating Agents
9.1.2. Platinum Compounds
9.1.3. Taxanes
9.2. Hormonal Therapy
9.2.1. Anti-Estrogens
9.2.2. Aromatase Inhibitors
9.3. Immunotherapy
9.3.1. Checkpoint Inhibitors
9.3.2. Vaccines
9.4. Targeted Therapy
9.4.1. Angiogenesis Inhibitors
9.4.2. PARP Inhibitors
9.4.3. Tyrosine Kinase Inhibitors
10. Gynecological Cancer Drugs Market, by Cancer Type
10.1. Cervical Cancer
10.2. Endometrial Cancer
10.3. Ovarian Cancer
10.4. Vulvar Cancer
11. Gynecological Cancer Drugs Market, by End User
11.1. Clinics
11.1.1. Oncology Clinics
11.1.2. Outpatient Clinics
11.2. Hospitals
11.2.1. Private Hospitals
11.2.2. Public Hospitals
11.3. Specialty Centers
12. Gynecological Cancer Drugs Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Gynecological Cancer Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Gynecological Cancer Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Gynecological Cancer Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Gynecological Cancer Drugs Market
17. China Gynecological Cancer Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. AbbVie Inc.
18.7. Alnylam Pharmaceuticals, Inc.
18.8. Amgen Inc.
18.9. Apotex Pharmaceutical Holdings Inc.
18.10. AstraZeneca PLC
18.11. Bayer AG
18.12. Biocon Limited
18.13. Bristol-Myers Squibb Company
18.14. Clovis Oncology
18.15. Dr. Reddy's Laboratories Ltd.
18.16. Eli Lilly and Company
18.17. F. Hoffmann-La Roche Ltd.
18.18. Genentech Inc.
18.19. GlaxoSmithKline PLC
18.20. ImmunoGen, Inc.
18.21. Johnson & Johnson Services, Inc.
18.22. Merck & Co., Inc.
18.23. Novartis AG
18.24. Pfizer Inc.
18.25. Sanofi SA
18.26. Takeda Pharmaceutical Co., Ltd.
18.27. Teva Pharmaceutical Industries Ltd.
18.28. TherapeuticsMD Inc.
18.29. VBL Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 179. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 180. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 181. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 182. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 183. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 184. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 185. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 186. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 187. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 189. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 190. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 207. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 208. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 209. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 211. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 212. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 213. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 214. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 215. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 217. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 218. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 221. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 233. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 234. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 236. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 237. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 238. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 239. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 240. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 241. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 242. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 243. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 244. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 246. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 247. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 248. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 249. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 250. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 251. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 252. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 254. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 255. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 256. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 257. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 258. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 260. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 261. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 277. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 278. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 279. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 280. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 281. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 282. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 283. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 284. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 285. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 286. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 287. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 288. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 289. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 290. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 291. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 292. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 293. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 294. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 295. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 296. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 297. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 298. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 299. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 300. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 301. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 302. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 303. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 305. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 306. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 307. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 308. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 309. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
TABLE 310. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 311. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 312. NATO GYNE

Companies Mentioned

The key companies profiled in this Gynecological Cancer Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apotex Pharmaceutical Holdings Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline PLC
  • ImmunoGen, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD Inc.
  • VBL Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.06 Billion
Forecasted Market Value ( USD ) by 2032 $ 26.63 Billion
Compound Annual Growth Rate12.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Gynecological Cancer Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Gynecological Cancer Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Gynecological Cancer Drugs - Global Strategic Business Report - Product Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Gynecological Cancer Drugs Market Report 2025 - Product Image

Gynecological Cancer Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Next-Generation Gynecological Cancer Diagnostics Market Report 2025 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Next-Generation Gynecological Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From

About the Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs market is a specialized segment within the broader domain of Oncology Drugs, focusing on medications used in the prevention and treatment of cancers affecting the female reproductive organs. This category encompasses drugs for ovarian, cervical, uterine/endometrial, and other less common gynecologic cancers. Advances in the understanding of the pathophysiology of gynecologic cancers have led to the development of targeted therapies, immunotherapy, hormone therapies, and chemotherapy agents. The growth in this market is driven by a rising prevalence of gynecological cancers, increased awareness of women's health, and ongoing research and development leading to more precise and personalized treatment options. In the landscape of the Oncology Drugs sector, gynecological cancer treatments are vital because they address a distinct and critical patient population. Various market participants often collaborate with research institutions and engage in clinical trials to enhance existing treatments and innovate new therapeutic solutions, facilitating progress in women's oncological care. Prominent companies operating in the Gynecological Cancer Drugs market include Roche Holding AG, AstraZeneca, Novartis AG, Pfizer Inc., and Bristol-Myers Squibb Company. These firms are pivotal in the research and production of drugs that cater to gynecological oncology, continually advancing the standards of care through therapeutic breakthroughs and extensive research initiatives. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.